ACQ2 by Acquired
The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)
Mar 6, 2024
Lotte Bjerre Knudsen, Novo Nordisk’s Chief Scientific Advisor, shares her remarkable journey in discovering semaglutide, the molecule behind Ozempic. She reveals the initial skepticism faced in the 90s and her steadfast belief in its potential for weight loss, which was a goal from the start. Lotte discusses the complex mechanisms of GLP-1 agents, how they impact appetite and weight management, and the innovative pharmaceutical testing processes enhancing drug effectiveness. Her insights shed light on the collaborative spirit necessary in biomedical science.
01:00:36
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- GLP-1 agonists like Semaglutide work by increasing insulin levels and lowering glucagon levels for blood glucose control.
- Innovative chemical engineering efforts led to the development of Semaglutide with an extended half-life and increased weight loss outcomes.
Deep dives
The Science behind GLP1 Agonists for Weight Loss and Diabetes Treatment
GLP1 agonists like Lira Glutide and Semaglutide work by increasing insulin levels and lowering glucagon levels, thereby reducing blood glucose. They also slow down food absorption in the intestine, helping to stabilize blood glucose levels after eating. Additionally, these medications help individuals consume fewer calories, leading to weight loss. The availability of Semaglutide once weekly injection provided a longer-lasting effect with doubled weight loss outcomes by reducing energy intake compared to Lira Glutide.
